Distribution of Topical Nasal Medication Within the Nasal Cavity and Sinuses by Radiographic Comparison

Not Applicable

Completed

Interventions: Radiation: Sinus CT Scan
Drug: Omnipaque 240 Contrast Solution
Drug: Omnipaque 240 mg I/mL

Brief Summary: The purpose of this study is to determine the distribution of nasal sprays and nasal drops when used.

Detailed Description: The purpose of this study is to determine the distribution of nasal sprays and nasal drops when used. The study hypothesizes that nasal drops will reach the frontonasal region more often than nasal sprays.

Recruitment & Eligibility

Inclusion Criteria

Exclusion Criteria

signs or symptoms of acute or chronic paranasal sinus disease
history of sinus surgery
symptomatic deviated septum
active seasonal allergies
allergies to contrast
history of nasal polyposis
pregnant or breast feeding women
neck or back problems that would prevent a subject from kneeling on the floor and crouching over
currently taking metformin or amiodarone
students or stff under the direct supervision of the investigators
cognitive impairment
terminal illness

Arm && Interventions

Group	Intervention	Description
Nasal spray	Omnipaque 240 Contrast Solution	This arm of the study will contain subjects who will spray 2-4 sprays of a nasal contrast solution in their nares. Following administration of the spray, the subjects will then have a Xoran mini-CAT scan of their sinuses.
Nasal drop	Sinus CT Scan	This arm will contain subjects who will place two drops of a nasal contrast solution in each nose. Following administration of the nasal contrast, the subjects will then have a Xoran miniCAT scan of their sinuses.
Nasal spray	Sinus CT Scan	This arm of the study will contain subjects who will spray 2-4 sprays of a nasal contrast solution in their nares. Following administration of the spray, the subjects will then have a Xoran mini-CAT scan of their sinuses.
Nasal drop	Omnipaque 240 mg I/mL	This arm will contain subjects who will place two drops of a nasal contrast solution in each nose. Following administration of the nasal contrast, the subjects will then have a Xoran miniCAT scan of their sinuses.

Primary Outcome Measures

Name	Time	Method
To Measure the Distribution of Nasal Sprays and Drops.	2 months	CT scan scored for distribution contrast delivered by nasal spray or drops within subsets in the nasal cavity. The sinonasal cavity was divided into twenty-one subsites on each side of the nasal cavity. The interpreters scored for the presence (1) or absence (0) of contrast from the nasal spray or nasal drops within each subsite. Left and right sides were interpreted separately for a possible total score of 0-42 for each CT scan.

Secondary Outcome Measures